Study details
Enrolling now
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa
University of Alabama at Birmingham
NCT IDNCT06326476ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
12
Study length
about 2.2 years
Ages
18+
Locations
1 site in AL
About this study
This trial is testing siplizumab for Hidradenitis Suppurativa. Subjects will receive subcutaneous doses of siplizumab over 8 weeks, with different dosages tested. Assessments will be done weekly and biweekly to monitor safety and efficacy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Siplizumab
PhaseEARLY_Phase 1
DrugSiplizumab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
monoclonal antibody
Endpoints
Secondary: Improvement in Visual Analogue Scale (VAS) pain scores